AI-designed ‘companion therapeutic’ works alongside GLP-1 therapy through a complementary mechanism linked to healthy aging.
Hot on the heels of multiple references to GLP-1 receptor agonists as longevity drugs at the recent Aging Research and Drug Discovery meeting in Copenhagen, AI-powered biotech MindWalk revealed it is moving forward with a new approach to GLP-1s that extends beyond diabetes and obesity into longevity therapeutics. The Austin-based company, formerly known as ImmunoPrecise Antibodies, announced the development of a dual-pathway regimen that pairs its AI-designed GLP-1 analogs with a proprietary companion therapeutic, designed to work through a separate but complementary biological mechanism linked to healthy aging.
MindWalk says its platform uncovered a “previously unrecognized” connection between GLP-1 signaling and a second pathway involved in metabolic resilience, inflammation balance and cellular stress response. Based on these insights, the company designed a regimen intended for long-term preventive use that maintains the benefits of GLP-1 drugs while broadening their potential impact on healthspan. Little information was revealed about the companion therapeutic, which is described as an “exclusive asset” developed internally and not derived from existing products, but the specific target remains undisclosed.
The new longevity program builds on MindWalk’s earlier work to develop AI-designed GLP-1 peptides, which it claims matched or exceeded semaglutide in receptor activation assays. The new program now layers a second therapeutic dimension onto those GLP-1 designs, with the goal of enhancing efficacy, durability and patient adherence in chronic, healthspan-oriented applications.
“GLP-1 drugs have already transformed diabetes and obesity care, but their potential as healthspan medicines is only beginning to be recognized,” said MindWalk CEO Dr Jennifer Bath, adding that the company is not simply iterating on existing drugs. “We are uncovering first principles that enable the design of safe, durable GLP-1 analogs and a proprietary companion therapeutic that acts through a complementary longevity pathway.”
The company indicates its development plan includes optimizing long-acting GLP-1 analogs for more patient-friendly dosing, advancing the companion therapeutic for co-administration, and running in silico modeling to refine dosing schedules and sequence design. Interestingly, it also says that biomarkers of aging and healthspan endpoints are being incorporated into the preclinical prioritization process. Updates on lead selection for the companion therapeutic, as well as combination design parameters, are expected in the coming months.
